Table of Contents
Chapter 1. Global Antibody Drug Conjugate Market Executive Summary
1.1. Global Antibody Drug Conjugate Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Mechanism of Action
1.3.2. By Drugs
1.3.3. By Technology
1.3.4. By Indication
1.3.5. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Antibody Drug Conjugate Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer's Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Antibody Drug Conjugate Market Dynamics
3.1. Market Drivers
3.1.1. Increasing Cancer Prevalence
3.1.2. Advancements in ADC Technologies
3.1.3. Expanding Applications Beyond Oncology
3.2. Market Challenges
3.2.1. Complexity of Manufacturing Process
3.2.2. High Costs and Regulatory Hurdles
3.3. Market Opportunities
3.3.1. Development of Eco-friendly Drugs
3.3.2. Technological Advancements in Manufacturing
3.3.3. Expansion in Emerging Markets
Chapter 4. Global Antibody Drug Conjugate Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Antibody Drug Conjugate Market Size & Forecasts by Mechanism of Action 2022-2032
5.1. Segment Dashboard
5.2. Global Antibody Drug Conjugate Market: Mechanism of Action Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. CD30 Antibodies
5.2.2. ErbB2 Antibodies
Chapter 6. Global Antibody Drug Conjugate Market Size & Forecasts by Drugs 2022-2032
6.1. Segment Dashboard
6.2. Global Antibody Drug Conjugate Market: Drugs Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Adcetris
6.2.2. Blenrep
6.2.3. Enhertu
6.2.4. Kadcyla
6.2.5. Padcev
6.2.6. Trodelvy
Chapter 7. Global Antibody Drug Conjugate Market Size & Forecasts by Technology 2022-2032
7.1. Segment Dashboard
7.2. Global Antibody Drug Conjugate Market: Technology Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Cleavable Linker
7.2.2. Linkerless
7.2.3. Non-Cleavable Linker
Chapter 8. Global Antibody Drug Conjugate Market Size & Forecasts by Indication 2022-2032
8.1. Segment Dashboard
8.2. Global Antibody Drug Conjugate Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Blood Cancer
8.2.2. Breast Cancer
8.2.3. Lymphoma
8.2.4. Multiple Myeloma
8.2.5. Urothelial Cancer & Bladder Cancer
Chapter 9. Global Antibody Drug Conjugate Market Size & Forecasts by End User 2022-2032
9.1. Segment Dashboard
9.2. Global Antibody Drug Conjugate Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
9.2.1. Academic Research Institutes
9.2.2. Biopharmaceutical & Biotechnology Companies
9.2.3. Hospitals
9.2.4. Specialized Cancer Centers
Chapter 10. Global Antibody Drug Conjugate Market Size & Forecasts by Region 2022-2032
10.1. North America Antibody Drug Conjugate Market
10.1.1. U.S. Antibody Drug Conjugate Market
10.1.1.1. Mechanism of Action breakdown size & forecasts, 2022-2032
10.1.1.2. Drugs breakdown size & forecasts, 2022-2032
10.1.1.3. Technology breakdown size & forecasts, 2022-2032
10.1.1.4. Indication breakdown size & forecasts, 2022-2032
10.1.1.5. End User breakdown size & forecasts, 2022-2032
10.1.2. Canada Antibody Drug Conjugate Market
10.1.2.1. Mechanism of Action breakdown size & forecasts, 2022-2032
10.1.2.2. Drugs breakdown size & forecasts, 2022-2032
10.1.2.3. Technology breakdown size & forecasts, 2022-2032
10.1.2.4. Indication breakdown size & forecasts, 2022-2032
10.1.2.5. End User breakdown size & forecasts, 2022-2032
10.2. Europe Antibody Drug Conjugate Market
10.2.1. U.K. Antibody Drug Conjugate Market
10.2.1.1. Mechanism of Action breakdown size & forecasts, 2022-2032
10.2.1.2. Drugs breakdown size & forecasts, 2022-2032
10.2.1.3. Technology breakdown size & forecasts, 2022-2032
10.2.1.4. Indication breakdown size & forecasts, 2022-2032
10.2.1.5. End User breakdown size & forecasts, 2022-2032
10.2.2. Germany Antibody Drug Conjugate Market
10.2.3. France Antibody Drug Conjugate Market
10.2.4. Spain Antibody Drug Conjugate Market
10.2.5. Italy Antibody Drug Conjugate Market
10.2.6. Rest of Europe Antibody Drug Conjugate Market
10.3. Asia-Pacific Antibody Drug Conjugate Market
10.3.1. China Antibody Drug Conjugate Market
10.3.2. India Antibody Drug Conjugate Market
10.3.3. Japan Antibody Drug Conjugate Market
10.3.4. Australia Antibody Drug Conjugate Market
10.3.5. South Korea Antibody Drug Conjugate Market
10.3.6. Rest of Asia Pacific Antibody Drug Conjugate Market
10.4. Latin America Antibody Drug Conjugate Market
10.4.1. Brazil Antibody Drug Conjugate Market
10.4.2. Mexico Antibody Drug Conjugate Market
10.4.3. Rest of Latin America Antibody Drug Conjugate Market
10.5. Middle East & Africa Antibody Drug Conjugate Market
10.5.1. Saudi Arabia Antibody Drug Conjugate Market
10.5.2. South Africa Antibody Drug Conjugate Market
10.5.3. Rest of Middle East & Africa Antibody Drug Conjugate Market
Chapter 11. Competitive Intelligence
11.1. Key Company SWOT Analysis
11.2. Top Market Strategies
11.3. Company Profiles
11.3.1. Roche Holding AG
11.3.1.1. Key Information
11.3.1.2. Overview
11.3.1.3. Financial (Subject to Data Availability)
11.3.1.4. Product Summary
11.3.1.5. Market Strategies
11.3.2. GlaxoSmithKline PLC
11.3.3. Daiichi Sankyo Company, Limited
11.3.4. Seagen Inc.
11.3.5. ADC Therapeutics SA
11.3.6. ImmunoGen, Inc.
11.3.7. Astellas Pharma Inc.
11.3.8. Bayer AG
11.3.9. Takeda Pharmaceutical Company Limited
11.3.10. Sanofi S.A.
11.3.11. Sorrento Therapeutics, Inc.
11.3.12. BioNTech SE
11.3.13. AbbVie Inc.
11.3.14. AstraZeneca PLC
11.3.15. Pfizer, Inc.
Chapter 12. Research Process
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes